Clinical Trial Update: Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating odanacatib (MK-0822) for osteoporosis completed; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• odanacatib (odanacatib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Osteoporosis | Phase 3 | Status: COMPLETED | Results posted: 2017-05-16